Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201461 | 0.85 | OPRM1 (0.41) | MEN1KMT2AOPRD1SLC6A3KCNH2 | |
| SCHEMBL1741596 | 0.76 | MEN1 (0.72) | MEN1KMT2AOPRD1CYP2D6USP2 | |
| SCHEMBL219432 | 0.75 | MEN1 (1.00) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| SCHEMBL2794662 | 0.75 | MEN1 (1.00) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7006476 | 0.74 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Fluoride SCHEMBL27959930 | 0.74 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| SCHEMBL27485345 | 0.74 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL11456225 | 0.74 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Piperazine SCHEMBL28229145 | 0.74 | MEN1 (0.96) | MEN1KMT2AOPRD1SLC6A2SLC6A4 | |
| Propane SCHEMBL27542064 | 0.71 | MEN1 (0.82) | MEN1KMT2AOPRD1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257544-B1 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20040034019-A1 | Piperazine and piperidine derivatives | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-19 | — | — | US | disclosed |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-09 | — | — | US | disclosed |
| EP-1257544-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001058891-A2 | PIPERAZINE AND PIPERIDINE DERIVATIVES FOR TREATMENT OR PREVENTION OF NEURONAL DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034019-A1 | Piperazine and piperidine derivatives | GAP43, BDNF, NGF | MEN1 3736/4885KMT2A 2094/4885OPRD1 1717/4885 |
| US-20030191110-A1 | Modulators of the cholesterol biosynthetic pathway | SREBF2, SREBF1, CYP46A1 | MEN1 3768/4885KMT2A 2315/4885OPRD1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.